Incyte Corporation
SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS

Last updated:

Abstract:

The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Status:
Application
Type:

Utility

Filling date:

24 Feb 2022

Issue date:

8 Sep 2022